Xtant Medical (US:XTNT) Prnewswire·2025-04-23 12:00Core Viewpoint - Xtant Medical Holdings, Inc. has launched Trivium™, a next-generation demineralized bone matrix allograft aimed at improving bone grafting procedures through advanced technology and design [1][4]. Product Features - Trivium is designed with intertwined structures and interconnected porosity to enhance cell attachment and tissue ingrowth, creating an optimal healing environment [2]. - The product features superior moldability and handling characteristics, allowing for precise placement in various surgical applications [2]. - Trivium is processed using the proprietary BacteRinse® method, which preserves native bone morphogenetic proteins (BMPs) to ensure the delivery of essential bioavailable growth factors for bone repair [3]. Company Commitment - The launch of Trivium reflects Xtant Medical's commitment to innovation in regenerative medicine, providing surgeons with a reliable solution for diverse surgical needs [4]. - The product is now available through the company's nationwide distribution network of independent agents [4]. Company Overview - Xtant Medical Holdings, Inc. focuses on the design, development, and commercialization of orthobiologics and spinal implant systems, aiming to facilitate spinal fusion in complex procedures [5].